Press Releases

F2i—Italy's largest infrastructure fund, headed by Renato Ravanelli—has signed up to the United Nations-supported Principles for Responsible Investment (PRI), showing its commitment to incorporating ESG (Environmental Social Governance) principles at all levels of its investment and governance strategy.

Today, the Shareholders’ Meeting of F2i has appointed the new Board of Directors for the financial years 2019, 2020, 2021. The newly appointed directors are: Massimiliano Cesare (Chairman), Renato Ravanelli (appointed Chief Executive Officer), Franco Dalla Sega, Gianluca Ghersini, Diego Buono; Giancarlo Giorgi, Nunzio Luciano, Alberto Oliveti, Andrea Flumiani, Antonio Cabras, Giandomenico Genta, Roberto Pinza, Cesare Dosi.

Tomorrow, February 6th, the Project Finance International (PFI) Award for the “European Solar Deal of the Year” will be presented in London to F2i, Italy’s leading infrastructure fund, led by Renato Ravanelli. The operation for which the F2i team will receive the award during a gala dinner at the Park Lane Hilton is the acquisition – for 1.3 billion euro – of the solar company RTR, together with its 334 MW of operating plants, from the English fund Terra Firma.

Today, F2i SGR, on behalf of Third F2i Fund, has acquired 50% of EF Solare Italia SpA from Enel Green Power SpA, thus becoming its sole shareholder. Thanks to the operation, the installed capacity fully owned by F2i in the photovoltaic (PV) industry will grow to more than 800 MW and will help restructure the company’s portfolio in order to achieve the expected scale synergies. F2i aims to further expand its managed portfolio, also by developing foreign business – commented the CEO Renato Ravanelli. F2i will strongly support and seize the opportunities offered by the expected technological developments in the sector.

Farmacie Italiane, a company in which Terzo Fondo F2i has a 61.2% controlling stake, has completed the purchase from Mr. Vincenzo Crimi of 100% of the share capital of Gruppo Farmacrimi that owns 12 pharmacies and 14 parapharmacies situated mainly in the Metropolitan City of Rome, plus one company active in the wholesale distribution of pharmaceuticals.